BY AND BETWEENTermination and Transition Agreement • March 15th, 2005 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • August 18th, 2020 • Altisource Asset Management Corp • Real estate • New York
TERMINATION AND TRANSITION AGREEMENT, dated as of August 13, 2020 (this “Agreement”), by and among Front Yard Residential Corporation, a Maryland corporation (the “Company”), Front Yard Residential, L.P., a Delaware limited partnership (“FYR LP”), and Altisource Asset Management Corporation, a U.S. Virgin Islands corporation (the “Manager”).
EX-2.1 2 a13-7836_1ex2d1.htm EX-2.1 TERMINATION AND TRANSITION AGREEMENT DATED AS OF MARCH 18, 2013 BY AND AMONG NPS PHARMACEUTICALS, INC., TAKEDA GmbH, AND TAKEDA PHARMA A/S TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • May 5th, 2020 • New York
THIS TERMINATION AND TRANSITION AGREEMENT (this “Agreement”) is made and entered into as of March 18, 2013 (the “Effective Date”), by and among NPS Pharmaceuticals, Inc., a Delaware corporation (“NPS”), Takeda GmbH, a German company (formerly known as Nycomed GmbH) (“Takeda GmbH”), and Takeda Pharma A/S, a Danish company (formerly known as Nycomed Danmark ApS) (“Takeda Pharma” and, together with Takeda GmbH, “Takeda”). NPS and Takeda are sometimes referred to herein individually as a “Party” and together as the “Parties”.
TERMINATION AND TRANSITION AGREEMENT by and between BIOMARIN PHARMACEUTICAL INC., a Delaware corporation, and ARES TRADING S.A.Termination and Transition Agreement • January 7th, 2016 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
This Termination and Transition Agreement (this “Agreement”), dated as of October 1, 2015 (the “Agreement Date”), is made by and among BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”) and Ares Trading S.A., a corporation organized under the laws of Switzerland (“Merck Serono”). BioMarin and Merck Serono are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
TERMINATION AND TRANSITION AGREEMENT by and betweenTermination and Transition Agreement • February 29th, 2016 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
This Termination and Transition Agreement (this “Agreement”), dated as of October 1, 2015 (the “Agreement Date”), is made by and among BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”) and Ares Trading S.A., a corporation organized under the laws of Switzerland (“Merck Serono”). BioMarin and Merck Serono are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • March 15th, 2011 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to the Termination and Transition Agreement (this “First Amendment”) is signed as of September __, 2010 (the “Amendment Signing Date”) and effective as of October 1, 2010 (the “Amendment Effective Date”), by and among Wyeth LLC (formerly known as “Wyeth”), acting through its Wyeth Pharmaceuticals Division, a limited liability company organized and existing under the laws of the State of Delaware and having a principal place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426 (“Wyeth Parent”), Wyeth-Whitehall Pharmaceuticals LLC (formerly known as Wyeth-Whitehall Pharmaceuticals, Inc.”), a limited liability company having a principal place of business at Road No. 3, Kilometer 142.1, Guayama, Puerto Rico 00784, Wyeth-Ayerst Lederle LLC (formerly known as “Wyeth-Ayerst Lederle, Inc.”), a limited liability company having a principal place of business at 65th Infantry Road, Kilometer 9.7, Carolina, Puerto Rico 00987-4904, and AHP Manufacturing B.V., trading
August 13, 2020Termination and Transition Agreement • August 18th, 2020 • Altisource Asset Management Corp • Real estate
TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • May 12th, 2011 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations
This TERMINATION AND TRANSITION AGREEMENT (the “Agreement”), effective as of March 31, 2011 (the “Effective Date”), is made by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA (“Sunesis”), Biogen Idec MA Inc., a Massachusetts corporation, having a principal place of business at 14 Cambridge Center, Cambridge, MA (“Biogen Idec”), and Millennium Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 40 Landsdowne Street, Cambridge, MA (“MPI”). Sunesis, Biogen Idec and MPI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AND TRANSITION AGREEMENT BY AND AMONGTermination and Transition Agreement • August 5th, 2014 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Termination and Transition Agreement (this “Agreement”) is entered into on this 1st day of April 2014 by and between (1) Amgen Inc., a Delaware corporation with its principal place of business at 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA (“Amgen Inc”), (2) Amgen Manufacturing Limited, a corporation incorporated under the laws of the Islands of Bermuda with its principal place of business at Canon’s Court, 22 Victoria Street, Hamilton, HM 12, Bermuda (“Amgen”), and (3) Glaxo Group Limited, registered in England as company number 305979, doing business as “GlaxoSmithKline” and having its principal office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”). Each of Amgen Inc, Amgen and GSK is sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • April 21st, 2015 • Biotie Therapies Corp. • Pharmaceutical preparations • New York
This Termination and Transition Agreement (“Termination and Transition Agreement”) is made and entered into as of August 22, 2014 (the “Termination and Transition Effective Date”) by and between Biotie Therapies Inc. (formerly Synosia Therapeutics, Inc.), a corporation organized under the laws of the State of Delaware, with its principal office at 701 Gateway Blvd, Suite 350, South San Francisco, California 94080, United States (“Biotie Inc.”); Biotie Therapies AG (formerly Synosia Therapeutics AG and successor in the merger between Biotie Therapies AG and Biotie Therapies Holding AG (formerly Synosia Therapeutics Holding AG)), a company organized under the laws of Switzerland, with its principal office at Kohlenberg 3, 4051 Basel, Switzerland (“Biotie AG” and, collectively with Biotie Inc., “Biotie”) on the one hand, and UCB Biopharma S.P.R.L., a company organized under the laws of Belgium, with its principal office at Allée de la Recherche 60, B-1070 Brussels, Belgium (“UCB”), on the
TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • November 8th, 2007 • Medicines Co /De • Pharmaceutical preparations • Massachusetts
This Termination and Transition Agreement (the “Agreement”) is effective as of 1st July 2007 (the “Effective Date”) by and between THE MEDICINES COMPANY, a Delaware corporation having offices at 8 Campus Drive, Parsippany, New Jersey 07054 (“TMC”), NYCOMED DANMARK ApS, P.O. Box 88, Langebjerg 1 DK-4000 Roskilde, Denmark, a company duly organized and existing under the laws of the Kingdom of Denmark (“Nycomed”), and NYCOMED HOLDING ApS, P.O. Box 88, Langebjerg 1 DK-4000 Roskilde, Denmark, a company duly organized and existing under the laws of the Kingdom of Denmark (“Nycomed Parent”).
TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • February 24th, 2015 • Curis Inc • Biological products, (no disgnostic substances)
THIS TERMINATION AND TRANSITION AGREEMENT (the “Transition Agreement”) is made as of February 5, 2015 (the “Termination Date”), by and between DEBIOPHARM INTERNATIONAL S.A., a Swiss corporation having its principal place of business at Forum «après-demain», Chemin Messidor 5-7, 1006 Lausanne, Switzerland (“Debiopharm”), and CURIS, INC., a corporation established under the laws of the State of Delaware, USA, having its principal place of business at 4 Maguire Road, Lexington, MA 02421-3112, United States of America (“Curis”).
TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • March 10th, 2009 • Orasure Technologies Inc • Surgical & medical instruments & apparatus • Delaware
This Termination and Transition Agreement (this “Agreement”) is made and entered into as of this 31st day of October, 2008 (“Effective Date”), by and between Abbott Laboratories, an Illinois corporation with principal offices at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott), and OraSure Technologies, Inc., a Delaware corporation with principal offices at 220 East First Street, Bethlehem, Pennsylvania 18015 (“OraSure”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • March 14th, 2013 • Xenoport Inc • Pharmaceutical preparations • Delaware
THIS TERMINATION AND TRANSITION AGREEMENT (“Termination Agreement”) dated as of November 8, 2012 (“Termination Effective Date”), is entered into between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410 Central Expressway, Santa Clara, CA 95051 (“XenoPort”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”).
TERMINATION AND TRANSITION AGREEMENTTermination and Transition Agreement • August 5th, 2004 • Medimmune Inc /De • Biological products, (no disgnostic substances) • Delaware
A mark of [***] on this page indicates that confidential material has been omitted. This Exhibit, including the omitted portions, has been filed separately with the Secretary of the Securities and Exchange Commission pursuant to an application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
FIRST AMENDMENT TO THETermination and Transition Agreement • February 27th, 2017 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
This First Amendment to the AMENDED AND RESTATED TERMINATION AND TRANSITION AGREEMENT (“First Amendment”) is made on December 12, 2016 (“First Amendment Effective Date”) by and between:
ContractTermination and Transition Agreement • March 15th, 2010 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
